CERO common stock becomes a shell holding SRX shares post-close, with a 180-day lock-up preventing immediate liquidation. The go-shop period runs through ~Nov 5, 2026 — monitor for any superior proposals could trigger a higher bid. SRX's NYSE listing and CERO's OTCQB listing provides a liquid reference for CERO warrants (CEROW).
Price Chart
Executive Summary
CERO Therapeutics Holdings has agreed to sell its wholly-owned operating subsidiary (CERo Therapeutics, Inc.) to SRX Global in exchange for SRX common stock valued at $1,000,000, forgiveness of ~$8.25M in secured debt, and assumption of ~$1.56M in liabilities. The deal includes a 30-day go-shop period and is structured as a sale of pledged collateral under Delaware law, requiring no common stockholder vote.
Key Financial Metrics
Key Facts
- CERO sells its operating subsidiary CERo Therapeutics, Inc. to SRX Global Inc.
- Consideration: SRX common stock ($1M value), debt forgiveness ($8,249,643.77 outstanding), and assumption of ~$1,562,000 in liabilities
- 30-day go-shop period with ability to consider superior proposals; $750,000 termination fee if CERO accepts a superior offer
- Closing conditioned on SRX acquiring CERO's Series C/D/E preferred stock and Series A preferred holders converting or waiving rights
- No common stockholder vote required under Section 272 of DGCL; board and special committee unanimously approved
- 180-day lock-up on SRX shares received by CERO
- Buyer's obligations are not subject to a financing condition
Financial Impact
CERO receives $1M in SRX stock, debt relief of $8.25M, and liability assumption of ~$1.56M — total consideration ~$10.8M for its operating subsidiary. CERO common stockholders retain a shell entity with no operating business post-close.
Risk Factors
- Go-shop may not yield a superior proposal; CERO common holders get SRX stock with 180-day lock-up and no operating business
- Closing conditions include preferred stock conversions/waivers that may not be obtained
- Debt forgiveness eliminates ~$8.25M in secured debt but CERO retains ~$1.56M in assumed liabilities
- SRX's obligations are not subject to a financing condition, but buyer has no financing condition
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-107410 |
| Document: ea0307733-8k_cero.htm | 0001213900-26-107410 |
| Document: 0001213900-26-107410-index-headers.html | 0001213900-26-107410 |
| Document: 0001213900-26-107410-index.html | 0001213900-26-107410 |
| Document: 0001213900-26-107410.txt | 0001213900-26-107410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $0.0951 | awaiting T+20 | — | $0.005000 (+94.74%) |
Aug 31, 2026 8w ago | 8-K | $0.0120 $0.0105 | ▲ +12.50% | ▲ +13.68% | $0.005000 (+58.33%) |
Jul 13, 2026 15w ago | 25-NSE | $0.0150 $0.0100 | ▲ +33.33% | ▲ +36.52% | $0.005000 (+66.67%) |
Jun 26, 2026 17w ago | 8-K | $0.0110 $0.009700 | ▲ +11.82% | ▲ +11.56% | $0.005000 (+54.55%) |
Mar 11, 2026 32w ago | 8-K | $0.0350 $0.0340 | ▲ +2.86% | ▲ +3.38% | $0.005000 (+85.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers